Cytosorbents Corp — Form 8-K/A
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 48/100
What the filing says
CytoSorbents (NASDAQ: CTSO) reported Q3 2026 revenue of $9.7M (+3% YoY), gross margin of 75% (+5 pts), and achieved operating cash flow breakeven of +$43K (excluding $251K restructuring costs). Net loss improved 35% to $2.1M ($0.65/share) from $3.2M ($1.01/share) in Q3 2025. The 8-K/A amended prior results to correct non-cash foreign currency losses: Q3 net loss revised upward to $2.1M (from $1.8M) and 9M net loss to $12.0M (from $11.4M), with no impact on revenue, gross profit, or cash. Company pursuing four value drivers: (1) cash breakeven achieved; (2) rebuilding Germany sales (down 21% YoY); (3) DrugSorb-ATR FDA De Novo submission planned early 2027 for ticagrelor removal (37% less severe bleeding in 587-patient study; $300M–$1–2B market); (4) HemoDefend-BGA strategic partnerships using $16M prior government funding.
Why this rating
Breakeven is real but fragile; $60.6M market cap; core CytoSorb growth still challenged; FDA approvals speculative and years away.
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.